Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Takeda Chairman Hasegawa Gives Up Representative Rights
Yasuchika Hasegawa, chairman of Takeda Pharmaceutical, has given up his rights to represent the company, making CEO Christophe Weber the sole representative right holder for the leading Japanese drug maker.The company’s board of directors approved this change at their meeting…
To read the full story
Related Article
- Takeda CFO Roger to Resign in under 2 Years
June 25, 2015
- Weber to Become CEO of Takeda in April
March 4, 2015
- Takeda CEO Defends Millennium, Nycomed Acquisitions as “Not Failures”
June 30, 2014
- Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- Takeda’s Next Leader Weber to Take Up COO Role on April 1
March 3, 2014
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
BUSINESS
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…